Prolonged treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing

Peter G Rose

doi:10.1016/j.gore.2024.101458

Prolonged treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing

Gynecol Oncol Rep. 2024 Jul 11:54:101458. doi: 10.1016/j.gore.2024.101458. eCollection 2024 Aug.

Author

Peter G Rose¹

Affiliation

¹ Women's Health Institute, Cleveland Clinic Foundation, A-81, 9500 Euclid Ave., Cleveland, OH 44195, United States.

Abstract

•Next generation sequencing identified a BRCA 2 mutation in a patient with stage IVB neuroendocrine cancer of the cervix.•Treatment with rucaparib resulted in disease stabilization for 74 months.•The patient remains fully active working full time as a nurse and pursing a nurse practitioner degree.